Home/Filings/4/0000950170-25-107981
4//SEC Filing

Bain Capital Life Sciences Fund III, L.P. 4

Accession 0000950170-25-107981

CIK 0001464521other

Filed

Aug 12, 8:00 PM ET

Accepted

Aug 13, 4:00 PM ET

Size

29.4 KB

Accession

0000950170-25-107981

Insider Transaction Report

Form 4
Period: 2025-08-11
Transactions
  • Conversion

    Common Stock

    2025-08-11$15.20/sh+433,924$6,595,64512,448,158 total(indirect: See footnotes)
  • Conversion

    Common Stock

    2025-08-11+12,014,23412,014,234 total(indirect: See footnotes)
  • Conversion

    Series F Preferred Stock

    2025-08-1135,081,5640 total(indirect: See footnotes)
    Common Stock (12,014,234 underlying)
  • Conversion

    Subordinated Convertible Promissory Note

    2025-08-110 total(indirect: See footnotes)
    Exercise: $15.20Exp: 2029-01-24Common Stock (433,924 underlying)
Transactions
  • Conversion

    Common Stock

    2025-08-11$15.20/sh+433,924$6,595,64512,448,158 total(indirect: See footnotes)
  • Conversion

    Common Stock

    2025-08-11+12,014,23412,014,234 total(indirect: See footnotes)
  • Conversion

    Series F Preferred Stock

    2025-08-1135,081,5640 total(indirect: See footnotes)
    Common Stock (12,014,234 underlying)
  • Conversion

    Subordinated Convertible Promissory Note

    2025-08-110 total(indirect: See footnotes)
    Exercise: $15.20Exp: 2029-01-24Common Stock (433,924 underlying)
Transactions
  • Conversion

    Common Stock

    2025-08-11+12,014,23412,014,234 total(indirect: See footnotes)
  • Conversion

    Common Stock

    2025-08-11$15.20/sh+433,924$6,595,64512,448,158 total(indirect: See footnotes)
  • Conversion

    Series F Preferred Stock

    2025-08-1135,081,5640 total(indirect: See footnotes)
    Common Stock (12,014,234 underlying)
  • Conversion

    Subordinated Convertible Promissory Note

    2025-08-110 total(indirect: See footnotes)
    Exercise: $15.20Exp: 2029-01-24Common Stock (433,924 underlying)
Transactions
  • Conversion

    Common Stock

    2025-08-11+12,014,23412,014,234 total(indirect: See footnotes)
  • Conversion

    Common Stock

    2025-08-11$15.20/sh+433,924$6,595,64512,448,158 total(indirect: See footnotes)
  • Conversion

    Subordinated Convertible Promissory Note

    2025-08-110 total(indirect: See footnotes)
    Exercise: $15.20Exp: 2029-01-24Common Stock (433,924 underlying)
  • Conversion

    Series F Preferred Stock

    2025-08-1135,081,5640 total(indirect: See footnotes)
    Common Stock (12,014,234 underlying)
Transactions
  • Conversion

    Common Stock

    2025-08-11$15.20/sh+433,924$6,595,64512,448,158 total(indirect: See footnotes)
  • Conversion

    Subordinated Convertible Promissory Note

    2025-08-110 total(indirect: See footnotes)
    Exercise: $15.20Exp: 2029-01-24Common Stock (433,924 underlying)
  • Conversion

    Series F Preferred Stock

    2025-08-1135,081,5640 total(indirect: See footnotes)
    Common Stock (12,014,234 underlying)
  • Conversion

    Common Stock

    2025-08-11+12,014,23412,014,234 total(indirect: See footnotes)
Footnotes (4)
  • [F1]Each share of the Issuer's Series F Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 0.342466:1 basis immediately prior to the closing of the Issuer's initial public offering. These securities had no expiration date.
  • [F2]The outstanding principal amount of the Subordinated Convertible Promissory note automatically converted into shares of the Issuer's Common Stock upon consummation of the Issuer's initial public offering at a conversion price of 80% of the price per share in the Issuer's initial public offering.
  • [F3]Represents securities held directly by BCLS Fund III Investments, LP ("BCLS Fund III Investments").
  • [F4]Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of Bain Capital Life Sciences III General Partner, LLC ("BCLS Fund III GP"), which is the general partner of Bain Capital Life Sciences Fund III, L.P. ("BCLS Fund III"), which is the managing member of BCLS Fund III Investments GP, LLC ("BCLS Fund III Investments GP"), which is the general partner of BCLS Fund III Investments. As a result, each of BCLSI, BCLS Fund III GP, BCLS Fund III and BCLS Fund III Investments GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund III Investments. BCLSI, BCLS Fund III GP, BCLS Fund III and BCLS Fund III Investments GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

Issuer

Heartflow, Inc.

CIK 0001464521

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001875273

Filing Metadata

Form type
4
Filed
Aug 12, 8:00 PM ET
Accepted
Aug 13, 4:00 PM ET
Size
29.4 KB